OVID Ovid Therapeutics Inc.

2.39
-0.01  -0%
Previous Close 2.4
Open 2.42
Price To Book 2.1
Market Cap 95,492,493
Shares 39,955,018
Volume 351,507
Short Ratio
Av. Daily Volume 588,528
Stock charts supplied by TradingView

NewsSee all news

  1. Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  2. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  3. Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

    Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare

  4. Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  5. Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due YE 2019 or early 2020.
OV101 (gaboxadol)
Fragile X syndrome
Phase 2 open label data released September 23, 2019.
OV935 ENDYMION
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 data due mid-2020.
OV101 - NEPTUNE
Adolescents with Angelman syndrome
Phase 2 top-line data due 2H 2020.
TAK-935/OV935 (ELEKTRA)
Dravet Syndrome / Lennox-Gastaut Syndrome
Phase 1b/2a data due 1Q 2020.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

Latest News

  1. Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  2. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  3. Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

    Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare

  4. Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  5. Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  6. Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today